16352-73-1

Basic information

• Product Name: 4-Benzylidene-4,5-dihydro-2-(p-tolyl)oxazol-5-one
• Synonyms: 4-Benzylidene-4,5-dihydro-2-(p-tolyl)oxazol-5-one
• CAS NO: 16352-73-1
• Molecular Formula: C₁₇H₁₃NO₂
• Molecular Weight: 263.2906
• Mol File: 16352-73-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 397.6°Cat760mmHg
• Flash Point: 174.7°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 1.57E-06mmHg at 25°C
• Refractive Index: 1.602
• CAS DataBase Reference: 4-Benzylidene-4,5-dihydro-2-(p-tolyl)oxazol-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzylidene-4,5-dihydro-2-(p-tolyl)oxazol-5-one(16352-73-1)
• EPA Substance Registry System: 4-Benzylidene-4,5-dihydro-2-(p-tolyl)oxazol-5-one(16352-73-1)

Safety Data

• Hazardous Substances Data: 16352-73-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C17H13NO2/c1-12-7-9-14(10-8-12)16-18-15(17(19)20-16)11-13-5-3-2-4-6-13/h2-11H,1H3

Upstream product

• 874-60-2 4-methyl-benzoyl chloride 
• 99-94-5 p-Toluic acid 
• 27115-50-0 N-(4-methylbenzoyl)glycine 
• 100-52-7 benzaldehyde 

Downstream Products

• 896994-16-4 C₂₂H₂₄N₂O₂ 
• 1323140-67-5 C₂₂H₂₃ClN₂O₂ 
• 211364-35-1 C₂₂H₂₃ClN₂O₂ 
• 59490-37-8 (S)-methyl (4-methylbenzoyl)phenylalaninate 
• 59490-28-7 methyl (Z)-2-(4-methylbenzamido)-3-phenylacrylate 
• 1357572-01-0 3-benzylidene-4-(4-methylbenzoyl)-1H-[1,4]benzodiazepine-2,5(3H,4H)-dione 
• 1357572-16-7 C₃₀H₂₂N₄O 
• 1357572-45-2 C₃₀H₂₄N₄O₂ 
• 1357572-28-1 C₃₆H₂₈N₆ 

Relevant articles and documents

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2/LOX inhibitors

A new series of 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT-Q NMR, and mass spectroscopy) and elemental analyse

Catalytic aza-wittig reaction of acid anhydride for the synthesis of 4H-benzo[d][1,3]oxazin-4-ones and 4-benzylidene-2-aryloxazol-5(4H)-ones

Compared to the aza-Wittig reaction of aldehydes, ketones, amides, and esters, the aza-Wittig reaction of acid anhydride was always overlooked, which should be an important part of Wittig reactions. Here, the aza-Wittig reaction of anhydride and catalytic aza-Wittig reaction of anhydride were both developed with high yields, which provides an efficient method to synthesize of 4H-benzo[d][1,3]oxazin-4-ones and 4-benzylidene-2-aryloxazol-5(4H)-ones. The strategy of copper-catalyzed reduction of phosphine oxide was used and found effective for this transformation. Additionally, the one-pot catalytic aza-Wittig reaction of carboxylic acids was achieved. Furthermore, NMR experiments and Hammett plot recorded the process of catalytic aza-Wittig reaction of anhydride, which provides direct proof that the copper-catalyzed reduction of waste phosphine oxide is the key step in this transformation.